Please login to the form below
Chiesi
This page shows the latest Chiesi news and features for those working in and with pharma, biotech and healthcare.
AZ prepares to file COPD triple, taking on rival GSK
First to market in Europe was Chiesi with its Trimbow (formoterol fumarate, glycopyrronium and beclomethasone) product, although this has to be administered twice-daily while Trelegy and PT010 are dosed just
Latest news
-
Chiesi targets patient adherence via mobile app
Chiesi targets patient adherence via mobile app. Initiative will see asthma and COPD patients receive device training support. ... Patients using Chiesi’s app will be able to review their inhaler technique and can share this during their consultations
-
Daily Brief: Gottlieb sets out cell and gene pathway, NICE says no to Chiesi ultra-rare treatment and more
Daily Brief: Gottlieb sets out cell and gene pathway, NICE says no to Chiesi ultra-rare treatment and more. ... them. UK MARKET ACCESS. NICE says no to Chiesi’s rare disease drug.
-
Gottlieb sets out cell and gene pathway, NICE says no to Chiesi ultra-rare treatment and more
Gottlieb sets out cell and gene pathway, NICE says no to Chiesi ultra-rare treatment and more. ... them. UK MARKET ACCESS. NICE says no to Chiesi’s rare disease drug.
-
Chiesi's ultra-rare genetic disorder therapy wins European backing
Chiesi's ultra-rare genetic disorder therapy wins European backing. Lamzede is set to become the first approved therapy for Alpha-Mannosidosis. ... It’s the second most advanced product from Chiesi’s rare disease unit after its LSCD therapy Holoclar
-
AZ’s COPD triple data sets up market clash with GSK
In Europe it was pipped to the post by Chiesi, which got a green light for its Trimbow (formoterol fumarate, glycopyrronium and beclomethasone) product, but this medicine must be administered
More from news
Approximately 13 fully matching, plus 30 partially matching documents found.
Latest Intelligence
-
The good, the bad and the ugly
GSK, AZ and Chiesi are each playing in this new market.
-
Deal Watch May 2016
911. The Medicines Company/ Chiesi. Product acquisition. Acquisition of cardiovascular assets Cleviprex, Kengreal and rights to Argatroban.
-
Anticipating the future in healthcare
The technology was licensed from the Dutch bio company uniQure BV by Chiesi, a mid-sized, family-owned pharma company based in Parma, Italy. ... Paolo Chiesi, chairman of the board of directors, and Andrea Chiesi, CEO of Chiesi Farmaceutici, are part of
-
Deal Watch table for September 2013
Cornerstone Therapeutics/ Chiesi Farmaceutici. Acquisition (42 per cent). US speciality pharmaceutical company focused hospital and niche respiratory products. ... 2. Global rights excluding India, Pakistan and China. 3. Acquisition of the shares not
-
Pharma deals during October 2012
In keeping with Chiesi's marketing capabilities, the licence is for certain countries, including Europe, Turkey and CIS countries. ... 58. † Veloxis Pharmaceuticals / Chiesi Farmaceutici. Licence. LCP-Tacro (tacrolimus) immunosuppressant for kidney
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest appointments
-
Akinion’s Dr Richard Jones joins Holostem Terapie Avanzate
Dr Paolo Chiesi, chairman of the board at Holostem, said: “ On behalf of the Holostem board, I am delighted to welcome Richard to the company. “
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
M&F Health
Chiesi. Clic Sargent. Clinimed. Danone. Dig . Early Years Nutirion Partnership. Janssen.
-
Random42 Scientific Communication
Boston Biomedical. Boston Scientific . Bristol-Myers Squibb. BTG. Celgene. Ceva. Chiesi. Cidara Therapeutics.
-
Random42 Scientific Communication
Boston Biomedical. Boston Scientific . Bristol-Myers Squibb. BTG. Celgene. Ceva. Chiesi. Cidara Therapeutics.
-
Swordfish Advertising
Archimedes Pharma. Corporate. Chiesi. Fostair. Corporate. Clenil. Atimos. Danone. Infant feeding.
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
Featured jobs
- Senior Medical Writer, MedComms Agency
-
£40 - 55, 000 according to skills and experience benefits
-
Healthcare PR Senior Account Manager
-
Salary TBC
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
-
Senior Medical Writer
-
Salary is DOE
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Account Manager, Healthcare Advertising
-
£30 - 38, 000 (or -)
- Integrated Brand/ Digital Senior Account Director, London
-
Excellent package
-
Account Manager
-
Negotiable
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
-
Senior Training Manager - Surrey
-
Competitive Salary &Bonus
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Senior Strategist/ Planner, Healthcare Marketing, London
-
Excellent package
- Account Director or Senior Account Director
-
Salary TBC
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
-
Associate Scientific Director
-
Salary TBC
-
Sudler London - Account Director
-
Competitive
Subscribe to our email news alerts
- Moving annual total (MAT)
- AZ prepares to file COPD triple, taking on rival GSK
- Key success factor (KSF)
- Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma
- Teva wins FDA OK for crucial migraine drug
- Gilead targets hep B in half a billion dollar deal with Precision BioSciences
- Lucid limbers up for second annual sports day
- Cello poaches Astellas' Taylor, Con Franklin joins Ketchum, Uptake Strategies expands
- Hanover Health launches award, Firstlight spins off healthcare arm and more
- J&J files ‘breakthrough’ bladder cancer drug in US
- Boehringer’s Corsico to be new GSK drug dev leader
- More tell, less sell: HCP-centric comms
PMHub
Publicis Resolute
Publicis Life Brands Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
